OpenAlex returns at least ten distinct author entities named Subhasis Ray . The two papers under review β a 2026 soft-set topology paper and a 2008 fludarabine/Treg immunology study β belong to neither the dominant XIM University business profile nor evidently to each other. The fludarabine paper (University of Connecticut GCRC funding) and the topology paper (no funding) almost certainly reflect different individuals. Any single-author assessment therefore carries high uncertainty; per-paper evidence is more reliable than profile-level metrics here.
The topology paper is a careful theoretical contribution: its central iff-characterization (E1) is supported by formal coordinatewise continuity proofs, and two well-chosen counterexamples (E2: box vs product topology for A=N; E3: non-canonical diagonal topology) demonstrate precision about exactly where the analogy breaks. BGPT scores it 7/10 quality, 6/10 novelty; blindspots are that it is purely theoretical with no applications, and completeness/locally-convex/dual-module extensions are deferred. The immunology paper reports internally consistent dose-response and CTL data (e.g., Mart-1-specific lysis 40.3% at 40:1 E:T), but n=3 patients, in vitro-only design, and unreadable portions of Table 2 constrain inferential strength β self-rated quality 7/10, generality only 5/10.
Caveat: this citation trajectory belongs to the business-school profile, not verifiably to either paper's author β an illustration of why profile-level bibliometrics are unreliable for this name. Note that the 2019 spike (285 citations) comes from a co-authored higher-education sustainability paper where Ray is a middle author, so citation mass partly reflects collaboration networks rather than solo scientific leadership.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.